Regeneron

Kalender

	Est. tid*
2026-05-01	12:30	Kvartalsrapport 2026-Q1
2026-02-02	N/A	Bokslutskommuniké 2025
2025-10-31	12:30	Kvartalsrapport 2025-Q3
2025-08-01	12:30	Kvartalsrapport 2025-Q2
2025-06-13	N/A	Årsstämma
2025-05-20	N/A	X-dag kvartalsutdelning REGN 0.88
2025-04-29	-	Kvartalsrapport 2025-Q1
2025-02-20	-	X-dag bonusutdelning REGN 0.88
2025-02-04	-	Bokslutskommuniké 2024
2024-10-31	-	Kvartalsrapport 2024-Q3
2024-08-01	-	Kvartalsrapport 2024-Q2
2024-06-14	-	Årsstämma
2024-05-02	-	Kvartalsrapport 2024-Q1
2024-02-02	-	Bokslutskommuniké 2023
2023-11-02	-	Kvartalsrapport 2023-Q3
2023-08-03	-	Kvartalsrapport 2023-Q2
2023-06-09	-	Årsstämma
2023-05-04	-	Kvartalsrapport 2023-Q1
2023-02-03	-	Bokslutskommuniké 2022
2022-11-03	-	Kvartalsrapport 2022-Q3
2022-08-03	-	Kvartalsrapport 2022-Q2
2022-06-10	-	Årsstämma
2022-05-04	-	Kvartalsrapport 2022-Q1
2022-02-04	-	Bokslutskommuniké 2021
2021-11-04	-	Kvartalsrapport 2021-Q3
2021-08-05	-	Kvartalsrapport 2021-Q2
2021-06-11	-	Årsstämma
2021-05-06	-	Kvartalsrapport 2021-Q1
2021-02-05	-	Bokslutskommuniké 2020
2020-11-05	-	Kvartalsrapport 2020-Q3
2020-08-05	-	Kvartalsrapport 2020-Q2
2020-06-12	-	Årsstämma
2020-05-05	-	Kvartalsrapport 2020-Q1
2019-08-06	-	Kvartalsrapport 2019-Q2
2019-06-14	-	Årsstämma

Filter

År

Typ

Språk

Rensa

2025-05-15 20:02:43 Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments

2025-05-01 15:30:00 Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination 583,85 USD | -0,54%

2025-05-01 15:00:00 Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases 583,85 USD | -0,54%

2025-04-29 12:30:00 Regeneron Reports First Quarter 2025 Financial and Operating Results 566,45 USD | -7,37%

2025-04-28 13:01:41 Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma 611,50 USD | +3,02%

2025-04-28 13:00:32 EYLEA HD® (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Continued Safety and Efficacy and Highlight Early Real-World Outcomes for Patients with Serious Retinal Disease 611,50 USD | +3,02%

2025-04-22 12:00:00 Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines 580,95 USD | +3,87%

2025-04-21 22:05:00 Regeneron Announces Investor Conference Presentations

2025-04-18 21:00:22 Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application

2025-04-18 17:15:32 Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

2025-04-17 13:00:08 EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications 559,31 USD | +1,78%

2025-03-28 07:00:14 Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD) 640,83 USD | +0,64%

2025-03-25 21:05:00 Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025 636,84 USD | -3,29%

2025-03-12 02:32:16 Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem 692,23 USD | -4,42%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Regeneron

Kalender

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden